Reply : Apixaban Dosing in Chronic Kidney&#160;Disease : Differences Between U.S. and&#160;E.U. Labeling by M. Proietti & G.Y.H. Lip
Letters J A C C V O L . 6 9 , N O . 9 , 2 0 1 7
M A R C H 7 , 2 0 1 7 : 1 2 0 4 – 1 2
1212REPLY: Apixaban Dosing in Chronic
Kidney Disease
Differences Between U.S. and E.U. LabelingWe thank Dr. Brophy for his kind comments on our
recent paper (1). He highlights a relevant issue for the
use of apixaban in patients with atrial fibrillation (AF)
with severe chronic kidney disease (CKD). Indeed,
current European Medicines Agency (EMA) and U.S.
Food and Drug Administration (FDA) indications
differ considerably (2,3).
In the EMA summary of product characteristics, for
patients with severe CKD (i.e., creatinine clearance
rate of 15 ml/min to 29 ml/min according to Cockroft-
Gault equation), apixaban plasma concentrations
were reported as increased up to 44% compared to
subjects with normal renal function (i.e., creatinine
clearance rate >80 ml/min) (2) when the 5-mg
twice-daily dose is administered. Based on this
consideration, EMA recommended use of the lower
apixaban dose (i.e., 2.5 mg twice daily) irrespective
of other criteria for dose reduction to avoid a
higher bleeding risk (3). EMA recommendations
have been also acknowledged and implemented by
the European Heart Rhythm Association practical
guide on use of non–vitamin K antagonist oral
anticoagulants (NOACs) (4).
Even if the FDA reported similar pharmacokinetic
data, their recommendation was still to use apixaban
2.5 mg twice daily only when the patient qualifies for
2 of the 3 criteria used in the main phase III study
(age $80 years, weight #60 kg and serum creatinine
level $1.5 mg/dl), irrespective of creatinine clearance
(3), notwithstanding the fact that the phase III trial
excluded patients with a Cockcroft-Gault creatinine
clearance rate <25 ml/min.
Interestingly, the FDA recommended use of apix-
aban 5 mg twice daily (and without any further dose
adjustment) in AF patients with end-stage renal
disease undergoing hemodialysis. Indeed, systemic
exposure to apixaban 5 mg twice daily followedby a dialysis procedure was 17% higher compared
to patients with normal renal function (5). In
contrast, the EMA label did not support the use of
apixaban in AF patients with end-stage renal
disease.
As Dr. Brophy suggests, we believe that these data
should be known by all physicians when making
decisions on which NOACs to prescribe in patients
with different degrees of renal disease. Given the
high risk of patients with CKD in terms of thrombo-
embolic and bleeding risks, caution is needed when
NOACs are used in these patients.Marco Proietti, MD
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